PTK2 and cancer: Initial in vitro evaluations showed that IN10018 has moderate to good efficacy against KRAS mutant cancer cell lines (Figure 2A); we confirmed significant inhibition of FAK activity for the examined cell lines (Figure S3A–G, Supporting Information).